Abstract
Rheumatoid arthritis (RA) is one of the chronic inflammatory autoimmune
diseases which occurs as a result of unknown reasons. This study was conducted at
Baghdad Teaching Hospital/City of Medicine, where blood samples were taken
from 60 Iraqi patients with RA (49 females and 11 males) and these patients were
matched by age and sex with 20 healthy controls (16 females and 4 males). Patients
with RA were diagnosed by a consultant rheumatologist according to ACR /
EULAR criteria in 2010. In this study the patients were divided into four groups as
follows; the first group consisted of 12 patients treated with methotrexate (MTX),
the second group consisted of 10 patients treated with etanercept, the third group
consisted of 18 patients treated with a combination of MTX, etanercept and
prednisolone, the fourth group consisted of 20 patients treated with MTX and
etanercept. Enzyme linked immunosorbent assay (ELISA) was used to detect
CCL18/PARC antibodies, while a spectrophotometer (Humalyzer2000) was used for
the measurement of alkaline phosphatase (ALP). Serum levels of CCL18 / PARC
showed a significant increase in RA patients compared with healthy controls (p ≤
0.001). The levels of CCL18/PARC showed a significant correlation with disease
activity (CDAI), except in RA patients treated with etanercept. There was also no
significant correlation between CCL18/PARC and erythrocyte sedimentation rate
(ESR). The results showed a significant increase in serum levels of alkaline
phosphatase (ALP) was recorded in RA patients (with treatment) as compared to
healthy controls (p ≤ 0.001).
diseases which occurs as a result of unknown reasons. This study was conducted at
Baghdad Teaching Hospital/City of Medicine, where blood samples were taken
from 60 Iraqi patients with RA (49 females and 11 males) and these patients were
matched by age and sex with 20 healthy controls (16 females and 4 males). Patients
with RA were diagnosed by a consultant rheumatologist according to ACR /
EULAR criteria in 2010. In this study the patients were divided into four groups as
follows; the first group consisted of 12 patients treated with methotrexate (MTX),
the second group consisted of 10 patients treated with etanercept, the third group
consisted of 18 patients treated with a combination of MTX, etanercept and
prednisolone, the fourth group consisted of 20 patients treated with MTX and
etanercept. Enzyme linked immunosorbent assay (ELISA) was used to detect
CCL18/PARC antibodies, while a spectrophotometer (Humalyzer2000) was used for
the measurement of alkaline phosphatase (ALP). Serum levels of CCL18 / PARC
showed a significant increase in RA patients compared with healthy controls (p ≤
0.001). The levels of CCL18/PARC showed a significant correlation with disease
activity (CDAI), except in RA patients treated with etanercept. There was also no
significant correlation between CCL18/PARC and erythrocyte sedimentation rate
(ESR). The results showed a significant increase in serum levels of alkaline
phosphatase (ALP) was recorded in RA patients (with treatment) as compared to
healthy controls (p ≤ 0.001).
Keywords
alkaline phosphatase
Human Pulmonary Activation Regulated Chemokine
Rheumatoid arthritis